ImmuCell Corporation (NASDAQ:ICCC) is reporting second quarter financial results on Wednesday 12th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, ICCC is expected to report 2Q20 loss of $ 0.1 per share from revenue of $ 3000.00 million.
For the full year, analysts anticipate top line of $ 15174.00 million, while looking forward to loss of $ 0.23 per share bottom line.
Previous Quarter Performance
ImmuCell Corporation reported loss for the first quarter of $ 0.02 per share, from the revenue of $ 4.91 million. The quarterly earnings down 22.38 percent while revenues compared with the same quarter last year.
According to street consensus, revenue of was expected for the first quarter The bottom line results street analysts by $ 0.02 or , at the same time, top line results analysts by $ 9.40 million or .
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of ImmuCell Corporation
Stock Performance
According to the previous trading day, closing price of ICCC was $ 5.70, representing a 54.05 % increase from the 52 week low of $ 3.70 and a 29.89 % decrease over the 52 week high of $ 8.13.
The company has a market capital of $ 41.11 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”ICCC” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 13th July 2020, initiated by Aegis at Buy rating, with $ 14.00 target price.
ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus.
